Healthcare provider profile · identity verified

Payce Jo-Hanna Handler Haley

Internal Medicine · NORRISTOWN, PA · NPI 1639229651

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	168	58
Gabapentin	Gabapentin	145	37
Pantoprazole Sodium	Pantoprazole Sodium	125	50
Levothyroxine Sodium	Levothyroxine Sodium	122	37
Eliquis	Apixaban	115	47
Metoprolol Succinate	Metoprolol Succinate	115	41
Furosemide	Furosemide	113	42
Rosuvastatin Calcium	Rosuvastatin Calcium	99	27
Potassium Chloride	Potassium Chloride	97	30
Amlodipine Besylate	Amlodipine Besylate	90	31
Metoprolol Tartrate	Metoprolol Tartrate	88	18
Escitalopram Oxalate	Escitalopram Oxalate	81	17
Tamsulosin Hcl	Tamsulosin Hcl	79	27
Sertraline Hcl	Sertraline Hcl	78	20
Metformin Hcl	Metformin Hcl	52	16
Quetiapine Fumarate	Quetiapine Fumarate	49	11
Omeprazole	Omeprazole	48	20
Trazodone Hcl	Trazodone Hcl	48	14
Lisinopril	Lisinopril	46	13
Donepezil Hcl	Donepezil Hcl	45	suppressed
Mirtazapine	Mirtazapine	44	13
Duloxetine Hcl	Duloxetine Hcl	42	11
Midodrine Hcl	Midodrine Hcl	36	13
Carvedilol	Carvedilol	35	12
Hydralazine Hcl	Hydralazine Hcl	35	suppressed
Levetiracetam	Levetiracetam	35	suppressed
Losartan Potassium	Losartan Potassium	34	13
Buspirone Hcl	Buspirone Hcl	32	suppressed
Clopidogrel	Clopidogrel Bisulfate	30	11
Simvastatin	Simvastatin	30	suppressed
Citalopram Hbr	Citalopram Hydrobromide	29	suppressed
Nystatin	Nystatin	26	20
Bumetanide	Bumetanide	25	14
Latanoprost	Latanoprost	25	14
Amiodarone Hcl	Amiodarone Hcl	24	suppressed
Gentamicin Sulfate	Gentamicin Sulfate	24	suppressed
Bupropion Hcl Sr	Bupropion Hcl	23	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	23	suppressed
Famotidine	Famotidine	23	suppressed
Januvia	Sitagliptin Phosphate	23	suppressed
Memantine Hcl	Memantine Hcl	23	suppressed
Solifenacin Succinate	Solifenacin Succinate	23	suppressed
Spironolactone	Spironolactone	23	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	21	15
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	21	suppressed
Finasteride	Finasteride	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Montelukast Sodium	Montelukast Sodium	19	suppressed
Cephalexin	Cephalexin	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Prednisone	Prednisone	18	11
Chlorthalidone	Chlorthalidone	17	suppressed
Divalproex Sodium	Divalproex Sodium	17	suppressed
Meropenem	Meropenem	17	suppressed
Valsartan	Valsartan	17	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	17	suppressed
Baclofen	Baclofen	15	suppressed
Celecoxib	Celecoxib	15	suppressed
Cefuroxime	Cefuroxime Axetil	14	11
Jardiance	Empagliflozin	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Neupro	Rotigotine	14	suppressed
Tresiba Flextouch U-100	Insulin Degludec	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Digoxin	Digoxin	13	suppressed
Entresto	Sacubitril/Valsartan	13	suppressed
Letrozole	Letrozole	13	suppressed
Memantine Hcl Er	Memantine Hcl	13	suppressed
Nebivolol Hcl	Nebivolol Hcl	13	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Amantadine	Amantadine Hcl	12	suppressed
Atenolol	Atenolol	12	suppressed
Heparin Sodium	Heparin Sodium,porcine	12	suppressed
Linzess	Linaclotide	12	suppressed
Lyumjev Kwikpen U-100	Insulin Lispro-Aabc	12	suppressed
Metolazone	Metolazone	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	12
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Tramadol Hcl	Tramadol Hcl	12	12
Allopurinol	Allopurinol	11	suppressed
Fluticasone Propionate	Fluticasone Propionate	11	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	11	suppressed
Rivastigmine	Rivastigmine Tartrate	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error